Latest IPF Studies Also Support Esbriet for More Severe Lung Function Impairment
Treatment with Genentech‘s FDA-approved Esbriet (pirfenidone) has been shown in two independent studies to improve moderate to more severe lung function impairment in patients with idiopathic pulmonary fibrosis (IPF). The results of the studies were recently presented at the American Thoracic Society International Conference (ATS 2017) May 19-24 in Washington,…